About Revapharma LLP
Data last updated:
Revapharma LLP is a limited liability partnership (LLP) based in New, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 February 2020 and has been in existence for over 6 years.
The LLP is registered with the Registrar of Companies (ROC), Delhi, under LLPIN AAR-9430. Its GSTIN is 07ABBFR0512N1ZA (Delhi). The LLP holds 2 GST registrations, all of them active.
The LLP has a total obligation of contribution of ₹1 Lakh. It is led by designated partners Shishant Gupta and Gurpreet Sandhu Singh.
Its latest statement of accounts is for the year ended 31 March 2024. The registered office is at A – 4 Part A Mahipalpur Extended Abadi Of Village Mahipalpur, Main Vasant Kunj Road Opp. To Jagannath Complex, New, Delhi, India – 110037.
As per the financials filed for FY 2023, the LLP reported a revenue of ₹1.14 Cr, a decline of 84% compared to the previous year. For the same year it recorded EBITDA of ₹11.78 Lakh (EBITDA margin 10.3%).
As per MCA filings, the LLP has open charges of ₹50 Lakh on record. Court records list 1 case involving the LLP, including 1 filed against it.
For more details, the LLP can be reached via its website revapharma.com.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social Media
- Registered AddressA – 4 Part A Mahipalpur Extended Abadi Of Village Mahipalpur, Main Vasant Kunj Road Opp. To Jagannath Complex, New, Delhi, India – 110037
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Revapharma LLP FY 2024 filings available
Revapharma LLP reported revenue of ₹1.14 Cr (down 84% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR) of Revapharma LLP
Revenue fell 84% in the latest year. EBITDA rose 257% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Revapharma LLP
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Income and Expenditure | ||||
| Turnover | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• |
| Total Income | •••• | •••• | •••• | •••• |
| Purchases and Direct Costs | •••• | •••• | •••• | •••• |
| Personnel Expenses | •••• | •••• | •••• | •••• |
| Administrative Expenses | •••• | •••• | •••• | •••• |
| Interest | •••• | •••• | •••• | •••• |
| Depreciation | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• |
| Tax | •••• | •••• | •••• | •••• |
| Profit After Tax | •••• | •••• | •••• | •••• |
| Profit Transferred to Partners | •••• | •••• | •••• | •••• |
| Assets and Liabilities | ||||
| Partners' Contribution | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• |
| Secured Loans | •••• | •••• | •••• | •••• |
| Unsecured Loans | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• |
| Other Liabilities and Provisions | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• |
| Loans and Advances | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• |
Financial Ratios of Revapharma LLP
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|
| Profitability | ||||
| Net Profit Margin | •••• | •••• | •••• | •••• |
| Return on Partners' Funds | •••• | •••• | •••• | •••• |
| Return on Assets | •••• | •••• | •••• | •••• |
| Liquidity and Debt | ||||
| Current Ratio | •••• | •••• | •••• | •••• |
| Debt to Partners' Funds | •••• | •••• | •••• | •••• |
| Interest Coverage | •••• | •••• | •••• | •••• |
| Efficiency and Growth | ||||
| Asset Turnover | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• |
| Turnover Growth | •••• | •••• | •••• | •••• |
| Profit Growth | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form 8. The full year-wise statements and ratios of Revapharma are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Revapharma LLP
Revapharma LLP is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Xenosys Biotech Private Limited | ₹1.15 Cr (FY 2025) | •••• | •••• | -42.0% | •••• | Sanand, Gujarat, India |
| Abm Lab Private Limited | ₹1.15 Cr (FY 2020) | •••• | •••• | 13.0% | •••• | New Delhi, Delhi, India |
| Bonjour Health Care Private Limited | ₹1.15 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | New Delhi, Delhi, India |
| Foray Life Care Private Limited | ₹1.15 Cr (FY 2025) | •••• | •••• | 51.0% | •••• | Bengaluru, Karnataka, India |
| Taizi Pharma Private Limited | ₹1.15 Cr (FY 2023) | •••• | •••• | 184.0% | •••• | Bangalore, Karnataka, India |
| Revapharma LLP this company | ₹1.14 Cr (FY 2023) | •••• | •••• | -84.0% | •••• | New Delhi, Delhi, India |
| Osr Pharmaceuticals Private Limited | ₹1.14 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Delhi, India |
| Vrihad Health Care Private Limited | ₹1.14 Cr (FY 2024) | •••• | •••• | 66.0% | •••• | Chhattisgarh, Chattisgarh, India |
| Pyramid Formulations Private Limited | ₹1.14 Cr (FY 2023) | •••• | •••• | 16.0% | •••• | Salem, Tamil Nadu, India |
| Life Line Biotech Limited | ₹1.14 Cr (FY 2025) | •••• | •••• | -66.0% | •••• | New Delhi, Delhi, India |
| Ytiliga Private Limited | ₹1.14 Cr (FY 2024) | •••• | •••• | 30.0% | •••• | Delhi, India |
Peers are the five companies nearest above and the five nearest below Revapharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Designated Partners of Revapharma LLP
Revapharma has 2 current designated partners and 1 former designated partner. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shishant Gupta | Designated Partner | 04 Jun 2022 | 4 Years 4 Months | Current |
| Gurpreet Sandhu Singh Also directs: Reva Medicare Private Limited, Akira Pharma Private Limited, Akira Developers Private Limited and 2 more | Designated Partner | 17 Feb 2020 | 6 Years 7 Months | Current |
Charges & Borrowings of Revapharma LLP
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Feb 2021 | Daimler Financial Services India Private Limited | ₹50 Lakh | Open |
Total charge records: 1 View all charges
Legal Cases of Revapharma LLP
Revapharma LLP has 1 court case on record: 1 filed against it. All case is disposed. Status as checked on 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gurugram, Haryana | Civil suit | Filed against the company by Rsa Legal Solutions | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Revapharma LLP
Employment history and EPFO contributions of people linked to Revapharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
News related to Revapharma LLP
Recent Activity on Revapharma LLP
Revapharma LLP has 3 designated partner changes on record since 2020: 2 appointments and 1 cessation. The latest: Nizar Balan ceased to be Designated Partner on 04 Jun 2022.
Credit Ratings, Litigation & Regulatory Alerts for Revapharma LLP
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Revapharma LLP
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Revapharma LLP
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Revapharma LLP
Revapharma has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07ABBFR0512N1ZA | Delhi | Active | 13 Jun 2020 |
| 24ABBFR0512N1ZE | Gujarat | Active | 08 Nov 2023 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Revapharma LLP
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Revapharma LLP
Revapharma is an active limited liability partnership based in New, Delhi, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 17 February 2020 (6+ years old) and is registered under LLPIN AAR-9430.
Revapharma reported revenue of ₹1.14 Cr for FY 2023 (down 84% YoY).
Revapharma has 2 current designated partners:
- Shishant Gupta - Designated Partner
- Gurpreet Sandhu Singh - Designated Partner
Revapharma reported EBITDA of ₹11.78 Lakh (EBITDA margin 10.3%) for FY 2023, as per its filed financial statements.
The GSTIN of Revapharma is 07ABBFR0512N1ZA, registered in Delhi. The LLP has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 24ABBFR0512N1ZE (Gujarat).
The LLPIN (Limited Liability Partnership Identification Number) of Revapharma is AAR-9430. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Revapharma has 1 court case on record: 1 filed against it.
Revapharma was incorporated on 17 February 2020, making it 6+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Revapharma by revenue are Xenosys Biotech Private Limited, Abm Lab Private Limited, Bonjour Health Care Private Limited, Foray Life Care Private Limited, Taizi Pharma Private Limited and 5 more, all in the Pharma industry (Formulations).
Nizar Balan ceased to be Designated Partner on 04 Jun 2022. Shishant Gupta was appointed as Designated Partner on 04 Jun 2022. Gurpreet Sandhu Singh was appointed as Designated Partner on 17 Feb 2020.
Revapharma can be reached through the website revapharma.com. Its registered office is in New, Delhi, India.